Yom Chai enters into a strategic partnership with Kaneh-B

| By | Clinical Trials, Drug Development, Plant-Based Drugs

Yom Chai (Israel), a medical cannabis company, announced that it has entered into a strategic partnership with Kaneh-B (Israel) to co-found the development and clinical validation of a range of cannabis based ADHD products.

Yom Chai’s objective is to conduct scientific trials in Israel utilizing various Cannabinoid and Terpene profiles with the goal of realizing multiple successful discoveries. The company is collaborating with leading Israeli and American scientist and medical professionals to conduct scientific clinical trials in Israel targeting Autism, ADHD, Crohn’s Disease, Psoriasis and Sleep Disorder to formulate, manufacture and distribute a wide range of Cannabis based products to treat various medical conditions.

Founded in 2018, Kaneh- B is a research & development company which delivers clinical and pre-clinical CBD and natural compound-based products. Kaneh-B’s experts encompass 15 years of naturopathic blends and cannabis research. The company has developed a line of products, unique both in formulation and in method of application. These products envelop the Entourage effect with a unique combination of cannabinoids, terpenes and herbal compounds.

Six products out of Kaneh-B’s distinguished product line, have recently passed the five tests needed for the European dermal product approval. These products will soon be available in various European countries through an extensive network of distributors which Kaneh- B has already contracted with.

SOURCE: prnewswire
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.